Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axonics, Inc. stock logo
AXNX
Axonics
$70.98
$70.61
$66.59
$71.05
$3.63B0.82406,171 shsN/A
Penumbra, Inc. stock logo
PEN
Penumbra
$268.72
+0.7%
$279.68
$148.00
$310.00
$10.41B0.53443,992 shs235,921 shs
Smith & Nephew plc stock logo
SNN
Smith & Nephew
$28.65
+0.9%
$27.43
$23.69
$31.72
$12.54B0.68798,440 shs948,581 shs
Solventum Co. stock logo
SOLV
Solventum
$70.85
-2.5%
$69.71
$47.16
$85.92
$12.26BN/A1.25 million shs1.12 million shs
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axonics, Inc. stock logo
AXNX
Axonics
0.00%0.00%0.00%0.00%+4.95%
Penumbra, Inc. stock logo
PEN
Penumbra
0.00%-4.40%-9.92%-8.14%+35.06%
Smith & Nephew plc stock logo
SNN
Smith & Nephew
0.00%-0.63%+6.11%+9.67%+11.78%
Solventum Co. stock logo
SOLV
Solventum
0.00%-4.37%+4.93%-3.05%+14.48%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Axonics, Inc. stock logo
AXNX
Axonics
N/AN/AN/AN/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
4.7141 of 5 stars
3.44.00.03.74.12.51.9
Smith & Nephew plc stock logo
SNN
Smith & Nephew
2.1642 of 5 stars
1.03.02.50.03.10.03.1
Solventum Co. stock logo
SOLV
Solventum
1.9627 of 5 stars
3.15.00.00.02.90.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axonics, Inc. stock logo
AXNX
Axonics
2.00
HoldN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
2.88
Moderate Buy$302.4012.53% Upside
Smith & Nephew plc stock logo
SNN
Smith & Nephew
2.00
Hold$28.00-2.27% Downside
Solventum Co. stock logo
SOLV
Solventum
2.10
Hold$80.2913.32% Upside

Current Analyst Ratings Breakdown

Latest AXNX, SOLV, SNN, and PEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Solventum Co. stock logo
SOLV
Solventum
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$78.00 ➝ $87.00
5/9/2025
Solventum Co. stock logo
SOLV
Solventum
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$80.00 ➝ $78.00
5/1/2025
Smith & Nephew plc stock logo
SNN
Smith & Nephew
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$27.00 ➝ $28.00
4/30/2025
Solventum Co. stock logo
SOLV
Solventum
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$84.00 ➝ $80.00
4/25/2025
Smith & Nephew plc stock logo
SNN
Smith & Nephew
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/25/2025
Smith & Nephew plc stock logo
SNN
Smith & Nephew
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$320.00 ➝ $330.00
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$301.00 ➝ $318.00
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$315.00 ➝ $330.00
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$315.00 ➝ $330.00
(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axonics, Inc. stock logo
AXNX
Axonics
$366.38M9.90$0.13 per share561.96$12.59 per share5.64
Penumbra, Inc. stock logo
PEN
Penumbra
$1.24B8.39$2.56 per share105.01$29.88 per share8.99
Smith & Nephew plc stock logo
SNN
Smith & Nephew
$5.81B2.16$3.58 per share8.00$11.94 per share2.40
Solventum Co. stock logo
SOLV
Solventum
$8.31B1.48N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axonics, Inc. stock logo
AXNX
Axonics
-$6.09M-$0.12N/A80.66N/A-1.31%0.36%0.31%N/A
Penumbra, Inc. stock logo
PEN
Penumbra
$90.95M$1.06790.3553.642.831.17%9.74%7.35%7/29/2025 (Estimated)
Smith & Nephew plc stock logo
SNN
Smith & Nephew
$263M$2.1613.2614.331.26N/AN/AN/A8/5/2025 (Estimated)
Solventum Co. stock logo
SOLV
Solventum
N/A$2.1632.8012.911.94N/AN/AN/AN/A

Latest AXNX, SOLV, SNN, and PEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Solventum Co. stock logo
SOLV
Solventum
$1.19$1.34+$0.15$0.78$2.02 billion$2.07 billion
4/23/2025Q1 2025
Penumbra, Inc. stock logo
PEN
Penumbra
$0.66$0.83+$0.17$1.00$315.72 million$324.14 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Axonics, Inc. stock logo
AXNX
Axonics
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
Smith & Nephew plc stock logo
SNN
Smith & Nephew
$0.893.11%N/A41.20%N/A
Solventum Co. stock logo
SOLV
Solventum
N/AN/AN/AN/AN/A

Latest AXNX, SOLV, SNN, and PEN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/26/2025
Smith & Nephew plc stock logo
SNN
Smith & Nephew
semi-annual$0.44702.5%3/28/20253/28/20255/28/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axonics, Inc. stock logo
AXNX
Axonics
N/A
8.16
6.40
Penumbra, Inc. stock logo
PEN
Penumbra
0.02
6.01
3.25
Smith & Nephew plc stock logo
SNN
Smith & Nephew
0.63
2.51
1.11
Solventum Co. stock logo
SOLV
Solventum
2.45
1.15
0.83

Institutional Ownership

CompanyInstitutional Ownership
Axonics, Inc. stock logo
AXNX
Axonics
99.48%
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%
Smith & Nephew plc stock logo
SNN
Smith & Nephew
25.64%
Solventum Co. stock logo
SOLV
Solventum
N/A

Insider Ownership

CompanyInsider Ownership
Axonics, Inc. stock logo
AXNX
Axonics
1.85%
Penumbra, Inc. stock logo
PEN
Penumbra
4.20%
Smith & Nephew plc stock logo
SNN
Smith & Nephew
1.00%
Solventum Co. stock logo
SOLV
Solventum
0.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
Axonics, Inc. stock logo
AXNX
Axonics
61051.11 million50.16 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
3,90038.73 million36.59 millionOptionable
Smith & Nephew plc stock logo
SNN
Smith & Nephew
20,100437.96 million432.83 millionOptionable
Solventum Co. stock logo
SOLV
Solventum
22,000173.01 millionN/AOptionable

Recent News About These Companies

Solventum (NYSE:SOLV) Stock Rating Upgraded by Piper Sandler

New MarketBeat Followers Over Time

Media Sentiment Over Time

Axonics stock logo

Axonics NASDAQ:AXNX

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Penumbra stock logo

Penumbra NYSE:PEN

$268.72 +1.97 (+0.74%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$266.56 -2.16 (-0.80%)
As of 05/23/2025 06:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Smith & Nephew stock logo

Smith & Nephew NYSE:SNN

$28.65 +0.25 (+0.88%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$28.64 -0.01 (-0.05%)
As of 05/23/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

Solventum stock logo

Solventum NYSE:SOLV

$70.85 -1.81 (-2.49%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$71.00 +0.15 (+0.21%)
As of 05/23/2025 06:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.